AbbVie recently announced positive follow-up results for its pivotal Phase 3 Resonate trial, which evaluated Imbruvica as a treatment for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
"These results suggest ibrutinib continues to provide persistent responses over the long-term in patients with chronic lymphocytic leukemia, including those who are difficult to treat," Dr. John Byrd, a professor at the Ohio State University Comprehensive Cancer Center and lead investigator of the study, said. "As a clinician who has treated patients with CLL for more than 20 years, I'm pleased to see the potential for efficacy and safety responses to continue over an extended period of time."
Study results show continued survival rates in patients with CLL for up to four years. Imbruvica, a Bruton's tyrosine kinase (BTK) inhibitor and the first chemotherapy-free treatment for patients with CLL, led to longer progression free survival in the study. Additionally, three-year survival was longer for Imbruvica patients.
"The first pivotal RESONATE data on IMBRUVICA were presented three years ago at ASCO and represented the promise of a new standard of care in blood cancer treatment," Dr. Danelle James, head of clinical science at Pharmacyclics LLC, said. "We are pleased to continue to see very favorable responses and survival outcomes to Imbruvica in relapsed and refractory CLL patients now into the fourth year of study."